Advertisements



Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin

Theravance (TBPH) submits the NDA for its key c.....»»

Category: topSource: zacksNov 14th, 2017

Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin

Theravance (TBPH) submits the NDA for its key c.....»»

Category: topSource: zacksNov 14th, 2017

Theravance/Mylan Presents Phase III Data on COPD Candidate

Theravance Biopharma, Inc. (TBPH) and partner Mylan recently announced the presentation of additional efficacy and safe.....»»

Category: topSource: zacksMay 24th, 2017

Theravance Shares Rise on Approval of Glaxo"s COPD Therapy

Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy. Theravance Biopha.....»»

Category: smallbizSource: nytNov 17th, 2017

Mylan, Theravance announce successful phase III studies for COPD drug

Milan Pharmaceuticals (Nasdaq:MYL) announced today that a drug it is helping develop in partnership with Theravance Biopharma, Inc. (Nasdaq: TBPH) has shown promise in two Phase III efficacy studies treating patients with chronic obstructive pulmonary dis.....»»

Category: topSource: bizjournalsOct 20th, 2016

Theravance Shares Rise on Approval of Glaxo"s COPD Therapy

Zacks.....»»

Category: topSource: redinewsNov 18th, 2017

Your Daily Pharma Scoop: Heron Undervalued, Theravance Submits NDA, Nektar Continues To Surge

Your Daily Pharma Scoop: Heron Undervalued, Theravance Submits NDA, Nektar Continues To Surge.....»»

Category: topSource: seekingalphaNov 14th, 2017

Teva Submits BLA to FDA for Migraine Candidate Fremanezumab

Teva Pharma (TEVA) submits BLA seeking approval for its pipeline candidate, Fremanezumab, as a preventive treatment for migraine in the United States. Teva Pharmaceutical Industries.....»»

Category: worldSource: nytOct 19th, 2017

Theravance Biopharma (TBPH) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow

Theravance Biopharma (TBPH) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow.....»»

Category: topSource: seekingalphaSep 27th, 2017

Theravance Biopharma"s (TBPH) CEO Rick Winningham on Q2 2017 Results - Earnings Call Transcript

Theravance Biopharma"s (TBPH) CEO Rick Winningham on Q2 2017 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaAug 12th, 2017

Theravance Biopharma Inc (TBPH) CEO Rick E Winningham Bought $—45,……… of Shares

Related Stocks: TBPH,.....»»

Category: dealsSource: nytAug 11th, 2017

Theravance Biopharma (TBPH) Updates On Results From Phase 2b Study Of Velusetrag - Slideshow

Theravance Biopharma (TBPH) Updates On Results From Phase 2b Study Of Velusetrag - Slideshow.....»»

Category: topSource: seekingalphaAug 3rd, 2017

Cardiome"s Partner SteadyMed Submits NDA for PAH Injection

Cardiome Pharma Corp. (CRME) announced that its partner SteadyMed Ltd. (STDY) has submitted a new drug application (NDA) to the FDA for its lead candidate, Trevyent (treprostinil injection), for treatment of pulmonary arterial hypertension (PAH.....»»

Category: topSource: zacksJul 4th, 2017

Theravance (TBPH) Down 5.8% Since Earnings Report: Can It Rebound?

Theravance (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. .....»»

Category: topSource: zacksJun 13th, 2017

Theravance (TBPH) Down 5.8% Since Earnings Report: Can It Rebound?

It has been about a month since the last earnings report for Theravance Biopharma, Inc. TBPH. Shares have lost about 5.8% in that time frame, underperforming the market. read more.....»»

Category: blogSource: benzingaJun 13th, 2017

Theravance Biopharma"s (TBPH) CEO Rick Winningham on Q1 2017 Results - Earnings Call Transcript

Theravance Biopharma"s (TBPH) CEO Rick Winningham on Q1 2017 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaMay 9th, 2017

Theravance (TBPH) Up 17.5% Since Earnings Report: Can It Continue?

Theravance (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. A month has gone by since the last earnings report for Theravance Biopharma, Inc. TB.....»»

Category: topSource: zacksMar 30th, 2017

Theravance (TBPH) Q4 Loss Wider than Expected, Revenues Beat

Zacks.....»»

Category: topSource: redinewsFeb 28th, 2017

Theravance (TBPH) Q4 Loss Wider than Expected, Revenues Beat

Theravance Biopharma, Inc. (TBPH) reported fourth-quarter 2016 loss of $1.36 per share, much wider than both the Z.....»»

Category: topSource: zacksFeb 28th, 2017

Theravance Biopharma"s (TBPH) CEO Rick Winningham on Q4 2016 Results - Earnings Call Transcript

Theravance Biopharma"s (TBPH) CEO Rick Winningham on Q4 2016 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaFeb 28th, 2017

Is Theravance Biopharma Inc (TBPH) A Good Stock To Buy?

The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge funds have been producing disappointing net returns i.....»»

Category: topSource: insidermonkeyDec 9th, 2016